India's National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 56 formulations and also capped the ceiling prices of two formulations, reported The Economic Times.
The formulations include treatments for various diseases, including cardiac conditions, anxiety disorders, hepatitis C and diabetes.
Specifically, some of the drugs include sofosbuvir and ledipasvir used for treatment of hepatitis C.
The NPPA has also fixed the retail price of teneligliptin metformin used for the treatment of diabetes, and capped the ceiling prices of digoxin and furosemide oral liquids.
To read more NewsPoints articles, click here.